GlassScriptPhysician profile
Devonn L Bourg
NPI 1467919928
$3,733.14
in general payments reported to CMS, 2019-2025
43 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,409 · 2022: $290 · 2023: $103 · 2024: $706 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $717.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $621.58 | 2021-2025 | |
| Amgen INC. | $172.76 | 2021-2025 | Evenity, Prolia |
| Axsome Therapeutics, INC. | $144.28 | 2025 | Symbravo, Auvelity |
| Lilly USA, LLC | $143.66 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Phathom Pharmaceuticals, INC. | $124.08 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $108.39 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.98 | 2024-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $95.51 | 2023-2025 | Gemtesa, Myfembree |
| Organon LLC | $95.47 | 2022 | |
| Esperion Therapeutics, INC. | $92.65 | 2021-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $91.21 | 2021-2025 | Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $76.56 | 2021-2025 | |
| Glaxosmithkline, LLC. | $72.20 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Therapeuticsmd, INC. | $68.00 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devonn Bourg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.